5-Hydroxytryptamine-induced potentiation of endothelin-1 and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent

Hypertension

Volumn 35, Issue 1 II, 2000, Pages 244-248

  Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Arteries; Endothelin; Hormones; Norepinephrine; Protein kinases

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ENDOTHELIN 1; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NORADRENALIN; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN;

ANIMAL TISSUE; ARTERY CONSTRICTION; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; HYPERTENSION; ISOLATED ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TAIL ARTERY; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

EID: 0033970879     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.35.1.244     Document Type: Conference Paper

References (44)

1. Rapport MM. Serum vasoconstrictor (serotonin) V: the presence of creatinine in the complex: a proposed study of the vasoconstrictor principle. J Biol Chem. 1949;180:961-969.
2. Turla MB, Webb RC. Vascular responsiveness to 5-hydroxytryptamine in experimental hypertension. In: Fozard JR, ed. The Peripheral Actions of 5-Hydroxytryptamine. Oxford, UK: Oxford University Press; 1989: 327-353.
3. Henry PD, Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine. J Clin Invest. 1980;66:306-313.
4. Martin GR. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmac Ther. 1994;62:283-324.
5. Szabo C, Hardebo JE, Owman C. An amplifying effect of exogenous and neurally stored 5-hydroxytryptamine on the neurogenic contraction in rat tail artery. Br J Pharmacol. 1991;102:401-407.
6. Xiao XH, Rand MJ. Amplification by serotonin of responses to other vasoconstrictor agents in the rat tail artery. Clin Exp Pharmacol Physiol. 1989;16:725-736.
7. Medgett IC, Fearn HJ, Rand MJ. Serotonin enhances sympathetic vasoconstrictor responses in rat isolated perfused tail artery by activation of postjunctional serotonin-2 receptors. Clin Exp Pharmacol Physiol. 1984; 11:343-346.
8. Yildiz O, Smith JR, Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci. 1998;62:1723-1732.
9. Van Neuten JA, Janssen PAJ, deRidder W, Vanhoutte PM. Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit: effect of ketanserin (R 41 468). Eur J Pharmacol. 1982;77:281-287.
10. 1-like receptor mediating the amplifying action of 5-HT in the rabbit ear artery. Br J Pharmacol. 1992;107:550-555.
11. Purdy RE, Murray D. Serotonin-induced vasoconstriction and contractile synergism with noradrenaline: role of α-adrenoceptors. In: Mylecharane EJ, Angus JA, de la Lande IS, Humphrey PP, eds. Serotonin: Actions, Receptors, Pathophysiology. London, UK: Macmillan Press Ltd; 1989: 130-135.
12. Takiguchi Y, Hashimoto H, Nakashima M. Reciprocal potentiation of a vasoconstrictor response between 5-hydroxytryptamine and clonidine in the perfused mesenteric vascular bed of the rat. Arch Int Pharmacodyn. 1987;287:16-30.
13. Van Diest MJ, Verbeuren TJ, Herman AG. Vascular interactions between 5-hydroxytryptamine and 15-lipoxygenase metabolites of arachidonic acid. Eur J Pharmacol. 1993;231:267-274.
14. 2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation. 1993;87:874-880.
15. Schulze-Lohoff E, Zanner S, Ogilvie A, Sterzel RB. Vasoactive diadenosine polyphosphates promote growth of cultured renal mesangial cells. Hypertension. 1995;26:899-904.
16. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Regulation of serotonin-induced DNA synthesis of bovine pulmonary artery smooth muscle cells. Am J Physiol. 1994;266:L53-L60.
17. Watts SW. Serotonin activates the mitogen activated protein kinase pathway in vascular smooth muscle: use of the mitogen activated protein kinase kinase inhibitor PD098059. J Pharmacol Exp Ther. 1996;279: 1541-1550.
18. 2A receptor. Ann N Y Acad Sci. 1998;861:162-168.
19. 2A receptor signal transduction. J Pharmacol Exp Ther. 1998;284:346-355.
20. Yang BC, Nichols WW, Lawson DL, Mehta JL. 5-Hydroxytryptamine potentiates vasoconstrictor effect of endothelin-1. Am J Physiol. 1992; 262:H931-H936.
21. 2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery. J Pharm Pharmacol. 1995;47:310-316.
22. Adner M, Uddman E, Cardell LO, Edvinsson L. Regional variation in appearance of vascular contractile endothelin-B receptors following organ culture. Cardiovasc Res. 1998;37:254-262.
23. 2-Adrenoceptor agonists enhance responses to certain other vasoconstrictor agonists in the rat tail artery. Br J Pharmacol. 1989;96:539-546.
24. Medgett IC, Langer SZ. Heterogeneity of smooth muscle alpha adrenoceptors in rat tail artery in vitro. J Pharmacol Exp Ther. 1984;229: 823-830.
25. Adam LP, Hathaway DR. Identification of mitogen-activated protein kinase phosphorylation sequences in mammalian h-caldesmon. FEBS Lett. 1993;322:56-60.
26. Khalil RA, Menice CB, Wang CLA, Morgan KG. Phosphotyrosine-dependent targeting of mitogen-activated protein kinase in differentiated contractile vascular cells. Circ Res. 1995;76:1101-1108.
27. Katoch SS, Moreland RS. Agonist and membrane depolarization induced activation of MAP kinase in swine carotid artery. Am J Physiol. 1995; 269:H222-H229.
28. DiSalvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun. 1993;190:968-974.
29. Epstein AM, Throckmorton D, Brophy CM. Mitogen-activated protein kinase activation: an alternate signaling pathway for sustained vascular smooth muscle contraction. J Vasc Surg. 1997;26:327-332.
30. Koide M, Kawahara Y, Tsuda T, Ishida Y, Shii K, Yokoyama M. Endothelin-1 stimulates tyrosine phosphorylation and the activities of two mitogen-activated protein kinases in cultured vascular smooth muscle cells. J Hypertens. 1992;10:1173-1182.
31. B receptor blockade. Circulation. 1999;100:5-8.
32. Kimura A, Ohmichi M, Takeda T, Kurachi H, Ikegami H, Koike K, Masuhara K, Hayakawa J, Kanzaki T, Kobayashi M, Akabane M, Inoue M, Miyake A, Murata Y. Mitogen-activated protein kinase cascade is involved in endothelin-1-induced rat puerperal uterine contraction. Endocrinology. 1999;140:722-731.
33. Irons CE, Flynn MA, Mok LM. Reynolds EE. Endothelin and PDGF enhance arachidonic acid release and DNA synthesis in vascular smooth muscle cells. Am J Physiol. 1996;270:C1642-C1646.
34. 1-Adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase. J Pharmacol Exp Ther. 1999;290:28-37.
35. Uddin MR, Muthalif MM, Karzoun NA, Benter IF, Malik KU. Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension. 1998;31:242-247.
36. Abebe W, Agrawal DK. Role of tyrosine kinases in norepinephrine-induced contraction of vascular smooth muscle. J Cardiovasc Pharmacol. 1995;26:153-159.
37. Merkel LA, Rivera LM, Colussi DJ, Perrone MH. Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem Biophys Res Commun. 1993;192: 1319-1326.
38. Sauro MD, Thomas B. Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Exp Ther. 1993;267:1119-1125.
39. Laniyonu AA, Saifeddine M, Yang SG, Hollenberg MD. Tyrosine kinase inhibitors and contractile action of G-protein linked vascular agonists. Can J Physiol Pharmacol. 1994;72:1075-1085.
40. Balasubramaniam G, Lee HS, Mah SC. Differences in the chronic hypotensive mechanism of action of ketanserin in spontaneously hypertensive and Wistar-Kyoto rat. J Hypertens. 1994;12:7-14.
41. 2 receptor antagonists ketanserin and LY53857 on blood pressure in anesthetized spontaneously hypertensive rats. J Pharmacol Exp Ther. 1989;248:736-740.
42. Cohen ML. Vascular serotonin receptors and blood pressure regulation. Drug Dev Res. 1984;4:301-313.
43. B endothelin receptor antagonist bosentan. Can J Physiol Pharmacol. 1995;73:390-398.
44. 2B receptor antagonist LY272015 is antihypertensive in DOCA-salt hypertensive rats. Am J Physiol. 1999;276: H944-H952.